Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background Many patients with chronic idiopathic constipation (CIC) remain unsatisfied with their treatment options. Plecanatide is a pH-sensitive uroguanylin analog that increases fluid and ion movement into the gastrointestinal lumen, softening stools and encouraging motility, while limiting the risk of diarrhea.Aims The objective of this phase 2 study is to evaluate the safety and efficacy of once-daily oral plecanatide in patients with CIC and identify the most effective dose.Methods A 12-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study was conducted in patients aged 18-75 years and diagnosed with CIC based on modified Rome III criteria (< 3 complete spontaneous bowel movements [CSBMs] per week and infrequent loose stools without the use of laxatives). Participants were randomized to placebo or plecanatide 0.3, 1.0, or 3.0 mg. The primary efficacy endpoint was the proportion of overall CSBM responders. Key secondary endpoints included time to first CSBM, change in CSBM and spontaneous bowel movement (SBM) frequency rates, patient-reported outcomes, safety, and tolerability.Results Of 951 randomized participants, 946 were included in the modified intent-to-treat population. Plecanatide 0.3 and 3.0 mg significantly increased overall CSBM responder rates compared with placebo (0.3 mg, P = 0.016; 3.0 mg, P = 0.009). Plecanatide was associated with decreased time to first CSBM, significant increases in CSBM and SBM frequency, and decreased patient-reported constipation severity compared with placebo. Diarrhea was the most frequently reported treatment-emergent adverse event.Conclusions Plecanatide is a well-tolerated treatment that relieved the symptoms of CIC with a relatively low incidence of diarrhea.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pooled data showed that the use of plecanatide in adults with CIC leads to an increase in the number of CSBMs per week (MD 1.1, 95% CI 85-1.35) and SBMs per week (MD 1.66, 95% CI 1.37-1.94) and improves the quality-of-life scores.”
Citations
Cites
Heidelbaugh, J. J., Stelwagon, M., Miller, S. A., Shea, E. P., & Chey, W. D. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.67 · Cited by 157
Miner, P. B., Koltun, W. D., Wiener, G. J., De La Portilla, M., Prieto, B., Shailubhai, K., Layton, M. B., Barrow, L., Magnus, L., & Griffin, P. H. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.611 · Cited by 141 · cited 2×
“gov: NCT01982240 and NCT02122471), plecanatide, a structural analog of human uroguanylin, significantly improved constipation-related symptoms and was well tolerated in patients with CIC [5, 6].”
BackgroundResultGuanylate cyclase-C as a therapeutic target in gastrointestinal disorders
Waldman, S. A., & Camilleri, M. (2018) · Gut · doi:10.1136/gutjnl-2018-316029 · Cited by 120
Harris, L. A., Horn, J., Kissous-Hunt, M., Magnus, L., & Quigley, E. M. M. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0633-5 · Cited by 75
DeMicco, M., Barrow, L., Hickey, B., Shailubhai, K., & Griffin, P. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17734697 · Cited by 74
Miner, P. B., Surowitz, R., Fogel, R., Koltun, W. D., Drossman, D. A., Camilleri, M., Mangel, A. W., Barrow, L., Jacob, G. S., & Shailubhai, K. (2013) · Gastroenterology · doi:10.1016/s0016-5085(13)60585-5 · Cited by 32
Self-citationPlecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
Rao, S. S. C. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818777945 · Cited by 32
Research works printed but not linked: 1
- American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100:S1–S4.
Cited by
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S. J., Greer, K. B., Hanson, B., Harris, L. A., Ko, C. W., et al. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002227 · Cited by 56
Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach
Kaniecki, T., Hughes, M., & McMahan, Z. H. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2320205 · Cited by 18
Pharmacotherapeutic advances for chronic idiopathic constipation in adults
Bassotti, G., Usai–Satta, P., Berti, G., Lai, M., Villanacci, V., & Bellini, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2150076 · Cited by 14
Mlakar, L., Garrett, S. M., Watanabe, T., Sanderson, M., Nishimoto, T., Heywood, J., Helke, K. L., Pilewski, J. M., Herzog, E. L., & Feghali‐Bostwick, C. A. (2022) · Biomedicines · doi:10.3390/biomedicines10112861 · Cited by 6
“Peptides are being developed to treat a variety of human conditions, often for multiple implications, such as for neuroprotection [61–65], mitochondrial diseases [66,67], constipation [68], cancer [69–73], antimicrobials [74–77], and diabetes [78–80].”
Background
Metadata
- Authors
- Barish, C., Dorn, S., Fogel, R. P., Patel, R., & Rosenberg, J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Troy Gastroenterology (US)
- Bausch Health (United States) (US)
- Corresponding author
- Patel, Reema
- Venue
- Digestive Diseases and Sciences
- Published
- 2020-03-17
- Volume
- 66
- Issue
- 2
- Pages
- 537-540
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W3012294198
- Cited by
- 8
- References
- 7
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Salix Pharmaceuticals, Inc.
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- plecanatide, chronic idiopathic constipation, guanylate cyclase-C agonist, dose-ranging, diarrhea, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Chronic Disease, Constipation, Diarrhea, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Treatment Outcome, Natriuretic Peptides, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial. https://app.cochat.ai/papers/10.1007/s10620-020-06187-5
- The paper
- Barish, C., Dorn, S., Fogel, R. P., Patel, R., & Rosenberg, J. (2021). Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-020-06187-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.